ClinicalTrials.gg
CompletedNCT07057050Updated Nov 3, 2026

Constraint-induced Movement Therapy Versus Task-oriented Training On Upper Extremity Function Post-Botox Injection in Stroke Patients

An interventional study of The designed physiotherapy program and The Botulinum toxin injection in Constraint Induced Movement Therapy, Task Oriented Training and Botox Injection, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 3, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
45 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Stroke by Cairo University — 20 open to participants now, 22 under way, none of them phase 3. Stroke · Cairo University.

Enrollment
13th of 38
51 · median 40
Started
2025
with 11 others
No phase
38 of 41
19 open now
Registered
20th of 41
by date

Among the 41 studies in Stroke by Cairo University, this one is the 13th largest by enrollment of the 38 interventional ones that give a count, is one of 12 that started in 2025, is one of 38 with no phase, and was the 20th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

20 of the 41 studies in Stroke by Cairo University are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 45 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Stroke by Cairo University, or all of them as a file.
02

Study summary

This study will be conducted to determine the impact of Constraint-Induced Movement Therapy versus Task-Oriented Training on upper extremity function post-Botox injection in stroke patients.

Read the detailed description

Arm and hand movement problems are significant contributors to disability in stroke patients, with only 5% regaining full arm function and 20% regaining no functional use. Alternative strategies are needed to reduce long-term disability and upper limb impairment in hemiparesis patients. Previous studies have used various treatment methods, including botulinum toxin, but the degree of motor improvement depends on task complexity. Future research should focus on adjunct therapy, such as task-specific training and constrained induced therapy, in addition to botulinum toxin treatments, to facilitate functional improvement in spastic upper extremity.

03

Conditions studied

  • Constraint Induced Movement Therapy
  • Task Oriented Training
  • Botox Injection
  • Upper Extremity Function
  • Stroke

Browse trials for

04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study focuses on patients aged 45-60 years
  • Patients who have subacute spastic hemiplegia with occlusion of the middle cerebral artery
  • Patients who are able to maintain balance in sitting positions.
  • Patients are diagnosed with the affected upper extremity being the dominant side.
  • Physiotherapy sessions are initiated 3-7 days post-injection,
  • Patients have pre-injection Modified Ashworth scores equal to 2 (moderate spasticity) in wrist or elbow flexors.
  • Patients can actively extend joints at least 10° at metacarpophalangeal and interphalangeal joints and 20° at the wrist of the affected upper limb.

Exclusion criteria

Exclusion Criteria:

  • Joint immobility in the upper limb due to contracture, bony deformity, or heterotopic ossification
  • Significant cognitive deficits (Mini-Mental Status Examination score \<24).
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    constrained induced movement therapy

    Patients will undergo a 60-minute physiotherapy program, such as traditional upper extremity training, following botulinum toxin A injection, as well as constrained induced movement therapy tasks for 12 consecutive weeks.

    Other: The designed physiotherapy program · Drug: The Botulinum toxin injection · Other: Constrained induced movement therapy

  • Active comparator
    task-oriented training

    Patients will undergo a 60-minute physiotherapy program, such as traditional upper extremity training, following botulinum toxin A injection, as well as task-oriented training tasks for 12 consecutive weeks.

    Other: The designed physiotherapy program · Drug: The Botulinum toxin injection · Other: Task oriented training

  • Active comparator
    designed physical therapy program

    Patients will undergo a 60-minute physiotherapy program, such as traditional upper extremity training, following botulinum toxin A injection, for 12 consecutive weeks.

    Other: The designed physiotherapy program · Drug: The Botulinum toxin injection

Interventions

  • OtherThe designed physiotherapy program

    * Scapular and thoracic mobilization, active assisted and passive exercises, and positioning such as weight bearing on the affected upper limb. * Strengthening of the shoulder flexors and elbow and wrist extensors. * Stretching exercises of the spastic muscles (shoulder extensors, elbow and wrist flexors.)

  • DrugThe Botulinum toxin injection

    The injection of 1000 units per upper extremity will be done into the biceps brachii muscle at 2 sites, and 150 units into the flexor carpi radialis muscle at 1 site per muscle, using anatomical landmarks similar to routine electromyography.

  • OtherTask oriented training

    The training involves 30 minutes of bilateral functional tasks like carrying a block, grabbing and folding a towel, staking cups upright, holding a glass and drinking water, throwing a ball into a basket, and moving pegs.

  • OtherConstrained induced movement therapy

    The therapy session focuses on enhancing the affected arm's functional tasks, such as throwing a ball, holding a glass, combing hair, turning on and off a light switch, grasping and releasing blocks, pouring from glass to another, moving cups, and moving pegs. Participants are instructed to wear a restrictive mitt on their non-paretic hand for 6 hours a day for 4 days, 7 weeks, and 12 weeks, with the mitt removed for safety, hygiene, or agreed-on activities.

06

What researchers measure

Primary outcomes

  1. assessment of change of arm motor impairment

    The Fugl-Meyer Upper Extremity scale, validated and reliable, correlates well with upper extremity coordination. It includes four motor sub-items relevant to the affected upper limb: shoulder/elbow/forearm, wrist, hand, and speed/coordination. The test is conducted pre- and post-treatment, requiring volitional movement mixing synergies. The total Fugl-Meyer Upper Extremity scale takes 30-35 minutes, and items are scored using a 3-point ordinal scale. The patient's performance ranges from 0 to 2 on the scale.

    Time frame: at baseline and after 12 weeks

Secondary outcomes

  1. Evaluation of degree of spasticity

    The Modified Ashworth Scale is a 6-point scale used to measure spasticity in the affected upper limb. The score ranges from 0 to 4, with lower scores indicating normal muscle tone and higher scores indicating spasticity or increased resistance to passive movement. Muscle tone assessment is done in a comfortable, quiet room, with no nociceptive or exteroceptive stimuli. The patient is instructed to empty their bladder and release tight clothes before the assessment.

    Time frame: at baseline and after 12 weeks

  2. assessment of change of handgrip strength

    Maximal voluntary grip forces (MVGF) will be assessed using grip dynamometer. Subjects are seated in a wheelchair. The shoulder is placed at approximately 30 degrees of abduction and 0 degrees of flexion. The elbow is flexed at 90 degrees with the wrist in neutral position. Maximal voluntary grip forces are established as the highest values recorded during three maximal voluntary exertions separated by 2-minute rest intervals. The mean value for each hand was used for analysis

    Time frame: at baseline and after 12 weeks

  3. assessment of change of shoulder and elbow movement

    Kinovea software is a reliable method for measuring shoulder joint position sense, suitable for medical, rehabilitation, and sports environments. It accurately measures shoulder joint position up to 5 meters from an object and 90°-45° angle. Kinovea software also performs motion analysis, capturing shoulder flexion, abduction, elbow flexion, and extension movements. Cross marks are drawn on anatomical landmarks on the dominant upper limb.

    Time frame: at baseline and after 12 weeks

  4. assessment of change of upper limb function

    The Action Research Arm Test (ARAT) is a tool used to evaluate limb function in individuals with hemiplegia due to cortical damage. It measures a client's ability to handle objects of different sizes, weights, and shapes. The ARAT scores range from 0 to 57, with higher scores indicating better performance. The test is conducted pre- and post-treatment and consists of four subscales: grasp, grip, pinch, and gross movement. If a client fails on the most difficult task, the easiest task is performed, and the entire subscale is scored as zero.

    Time frame: at baseline and after 12 weeks

07

Study locations

1 site
  • outpatient clinics of Mansoura university hospital
    Al Mansurah, Egypt
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Feb 2026, 7 months.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 7 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Oct 2025 → Feb 2026 and completion Nov 2025 → Apr 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2025
First posted
Jul 9, 2025
StartActual
Jun 30, 2025
Primary completionActual
Feb 1, 2026was Oct 2025
CompletionActual
Apr 1, 2026was Nov 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2025→Feb 1, 2026
Nov 3, 2026
Study completion
Nov 1, 2025→Apr 1, 2026
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Primary completion Oct 1, 2025→Feb 1, 2026
    Study completion Nov 1, 2025→Apr 1, 2026
  2. Oct 20, 2026
    Minor edits only
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07057050
Lead sponsor
Cairo University
Responsible party
Reem Hesham Mohamed Abdelhady (principal investigator, Cairo University) — Principal investigator
First posted
Jul 9, 2025
Start date
Jun 30, 2025
Primary completion
Feb 1, 2026
Completion
Apr 1, 2026
Last update
Nov 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion